Sun Pharma gets USFDA nod for alopecia areata drug Leqselvi
Mumbai: Sun Pharmaceutical Industries Limited has announced that the U.S. Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia
areata.
Alopecia areata affects around 700,000 people in the United States, and 300,000 have severe alopecia
areata. Alopecia often leads patients to self-treat before seeking professional help, driven by
dissatisfaction with the slow progress of existing treatments.
“LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering
patients battling severe alopecia areata and their physicians,” said Abhay Gandhi, CEO, North America
Business, Sun Pharma. “Our fast-growing dermatology business is excited to add this novel treatment to
its portfolio.”
Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the
collapse of immune privilege, leading to the immune system targeting the hair follicles and causing
sudden hair loss on the scalp, face and sometimes other areas of the body.
LEQSELVI is a new, twice daily oral selective inhibitor of Janus Kinases (JAK) JAK1 and JAK2. As a JAK inhibitor, LEQSELVI interrupts
the pathways thought to contribute to hair loss in severe alopecia areata.
“We welcome the approval of LEQSELVI as a significant step for the alopecia areata community,” said
Nicole Friedland, President and CEO, National Alopecia Areata Foundation (NAAF). “Alopecia areata is an
autoimmune disease, with significant physical, emotional and financial impacts that go beyond hair loss.
The announcement empowers the alopecia community with even more choices, to which NAAF is
committed, and provides another important option for those living with severe alopecia areata.”
The approval is based on data from two multicenter, randomized, double-blind, placebo-controlled
Phase 3 clinical trials THRIVE-AA1 and THRIVE-AA2, which enrolled a total of 1,220 patients with alopecia
areata who had at least 50% scalp hair loss as measured by Severity of Alopecia Tool (SALT) for more than six months. Data were also collected from two open-label, long-term extension trials in which
patients were eligible to enroll upon completion of the 24-week trials.
At study baseline, the average patient had only 13% of their scalp hair coverage. In the trials, at 24
weeks, the primary endpoint was met, with more than 30% of patients taking LEQSELVI experiencing
80% or more scalp hair coverage (SALT ≤20).
The number of patients taking LEQSELVI and achieving a
SALT score of ≤20 showed a consistent upward trend with no plateau through 24 weeks. Additionally, up
to 25% of patients had almost all of their scalp hair back at 24 weeks (≥90% coverage).
“For many people with severe alopecia areata, early intervention with effective treatment is critical,” said
Natasha Mesinkovska, MD, PhD, Associate Professor and Vice Chair for Clinical Research of Dermatology,
University of California, Irvine, and investigator in the LEQSELVI clinical development program. “An oral
JAK that delivers proven results will be impactful for the alopecia areata community.”
Across the Phase 2 dose-ranging study and Phase 3 randomized, placebo-controlled trials, few patients
(3.1%) receiving LEQSELVI 8 mg twice daily were discontinued from the trials due to adverse reactions. In clinical trials, more than 100 people continued taking deuruxolitinib for more than three years. LEQSELVI may cause serious side effects including serious infections, malignancies, thrombosis,
gastrointestinal perforations, and certain laboratory abnormalities. There also may be an increased risk
of mortality and major cardiovascular events. LEQSELVI should not be used in patients who are CYP2CP
poor metabolizers or who are taking moderate or strong CYP2C9 inhibitors.
“We are pleased with the timely approval of LEQSELVI by the U.S. FDA,” said Marek Honczarenko, MD,
PhD, Senior Vice President, Head of Development, Sun Pharma. “This validates our team’s capability to
effectively bring treatments from research and development to approval in a way that is meaningful for
physicians and patients. I want to thank all the investigators and patients for their participation in the
clinical trials.”
